Impact of LDL-Cholesterol When the Coronary Artery Calcium Score Is 0: Long-Term Cardiovascular Events [0.03%]
冠脉钙化得分为0的患者中LDL胆固醇对长期心血管事件的影响
Allison W Peng,Alexander C Razavi,John T Wilkins et al.
Allison W Peng et al.
Dietary and Lifestyle Habits of Cardiologists: Perception vs Practice [0.03%]
心脏病专家的饮食和生活习惯：认知与实际之间的差异
Kim Allan Williams Sr,Mashaal Ikram,Beth Frates et al.
Kim Allan Williams Sr et al.
The Pathophysiologic Basis and Management of Calcific Aortic Valve Stenosis: JACC State-of-the-Art Review [0.03%]
钙化性主动脉瓣狭窄的病理生理基础和管理：JACC最新进展评论
Milind Y Desai,Eugene Braunwald
Milind Y Desai
Calcific aortic valve stenosis (CAVS) is the most frequent valve disorder in adults, with a steadily increasing incidence with age. Currently, no effective treatments are available to prevent or delay disease progression. In addition to pro...
Neurocognitive Outcomes in Adults With Congenital Heart Disease: MIND the Gap [0.03%]
小心谨慎：关于先天性心脏病成人患者的神经认知结果研究
Shabnam Peyvandi,Roberta G Williams
Shabnam Peyvandi
Prevalence and Predictors of Neurocognitive Dysfunction in Adults With Congenital Heart Disease: Results From MINDS-ACHD [0.03%]
成人先天性心脏病患者神经认知功能障碍的患病率及预测因素——Minds-Achd研究结果
Scott Cohen,Michelle Gurvitz,Kristin M Burns et al.
Scott Cohen et al.
Background: Adults with congenital heart disease (ACHD) undergo repeated cardiac interventions, develop cardiac complications including atrial fibrillation, heart failure, and stroke, and may have genetic vulnerabilities ...
The Disquieting Plateau [0.03%]
不安的高原
Harlan M Krumholz
Harlan M Krumholz
Echocardiographic Changes With Mavacamten in Nonobstructive Hypertrophic Cardiomyopathy: Exploratory Insights From the ODYSSEY-HCM Trial [0.03%]
非梗阻性肥厚型心肌病 mavacamten 治疗的经胸超声心动图变化：ODYSSEY-HCM 研究初步分析
Milind Y Desai,Yuichiro Okushi,Shada Jadam et al.
Milind Y Desai et al.
Background: Symptomatic nonobstructive hypertrophic cardiomyopathy (nHCM) lacks approved therapies. The ODYSSEY-HCM trial (A Study of Mavacamten in Non-Obstructive Hypertrophic Cardiomyopathy; NCT05582395), the largest to...
Effects of Mavacamten on Cardiac Biomarkers in Nonobstructive Hypertrophic Cardiomyopathy: Insights From the ODYSSEY-HCM Trial [0.03%]
mavacamten对非流出道肥厚型心肌病心脏生物标志物的影响：来自ODYSSEY-HCM试验的启示
Milind Y Desai,Iacopo Olivotto,Theodore Abraham et al.
Milind Y Desai et al.
Background: No therapy is approved for patients with symptomatic nonobstructive hypertrophic cardiomyopathy (nHCM). The ODYSSEY-HCM (A Study of Mavacamten in Non-Obstructive Hypertrophic Cardiomyopathy [ODYSSEY-HCM]; NCT0...
Adiposity-Related Anthropometrics and Clinical Outcomes in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Participant-Level Pooled Analysis of Randomized Clinical Trials [0.03%]
与心力衰竭（轻度降低或保留射血分数）相关的肥胖体型特征和临床结果：随机临床试验的参与者水平汇总分析
John W Ostrominski,Mats C Højbjerg Lassen,Jawad H Butt et al.
John W Ostrominski et al.
Background: Obesity is highly prevalent among individuals with heart failure with mildly reduced ejection fraction (HFmrEF) or heart failure with preserved ejection fraction (HFpEF) and is associated with increased risk o...